This Management Discussion and Analysis Report provides an overview of the Companys business operations, financial performance, industry developments, future outlook, plans and expectations. The statements contained in this Report describing the Companys objectives, projections, estimates, expectations or predictions may constitute forward-looking statements within the meaning of the applicable laws and regulations. Actual results may differ materially from those expressed or implied in such statements due to various risks, uncertainties and other factors beyond the Companys control.
Industry overview
During the Financial Year 2025-26, the Indian pharmaceutical and nutraceutical industry continued to witness steady growth, driven by increasing healthcare awareness, rising demand for preventive healthcare, wellness products and health supplements, changing consumer lifestyles, and favourable demographic trends. The industry offers significant long-term growth opportunities, supported by expanding healthcare infrastructure and an increasing focus on quality, innovation and regulatory compliance.
The Company is in the initial stages of establishing its presence in this sector and is gradually building its business in line with its revised business objectives. As the business expands, the Company aims to capitalize on emerging opportunities and achieve sustainable growth while ensuring compliance with the applicable regulatory framework.
Review of financial and operating performance
During the Financial Year 2025-26, the Company did not generate any revenue from operations on a standalone basis. However, after considering other income, the Company reported a standalone profit of Rs54.20 lakhs for the year. The financial performance was impacted by the mandatory and essential expenses incurred by the Company.
1. Paid up share capital
The paid-up equity share capital of the Company stood at Rs 559.12 lakhs as on March 31,2026, comprising 55,91,164 equity shares of Rs10 each.
2. Reserves and Surplus
The Reserves and Surplus of the Company stood at Rs1,568.23 lakhs as on March 31,2026 as compared to Rs642.85 lakhs as on March 31,2025. The increase was primarily on account of the Securities Premium arising from the preferential allotment of equity shares and the conversion of warrants into equity shares pursuant to the allotments made on April 5, 2025 and December 13, 2025, together with the profit earned during the year.
3. Secured/ Unsecured Loan
The Company has not availed any secured or unsecured loans during the Financial Year 2025-26.
4. Turnover
During the Financial Year 2025-26, the Company did not generate any revenue from operations on a standalone basis. However, on a consolidated basis, the Company reported revenue from operations of Rs267.08 lakhs.
5. Profits /Loss
During the Financial Year 2025-26, despite incurring mandatory and essential operating expenses and recognizing a one-time exceptional item relating to the impairment on the fair valuation of investments, the Company reported a standalone profit of Rs54.20 lakhs. On a consolidated basis, the Company incurred a loss of Rs694.49 lakhs during the year.
BUSINESS ANAYSIS
During the Financial Year 2025-26, the Company had initiated the pharmaceutical, nutraceutical and wellness business in line with its revised main objects. However, during the year the Company could not commence any activities relating to the said new business due to procedural and licensing requirements. The Company is in the initial stages of establishing its business and gradually expanding its operations in the sector. The Company through its subsidiary TruHealthy Wellness Private Limited, has started the marketing and distribution set up for _the wellness and pharma products.
The pharmaceutical and nutraceutical industry offers significant long-term growth opportunities, driven by increasing healthcare awareness, rising demand for preventive healthcare, wellness products and health supplements, and favourable demographic trends. The Company continues to evaluate business opportunities with a focus on sustainable growth, operational efficiency and compliance with the applicable regulatory framework.
Opportunities and risks
Opportunities
The healthcare, pharmaceutical and wellness sector continues to offer substantial opportunities owing to increasing consumer preference for quality healthcare products and preventive wellness solutions. The evolving healthcare ecosystem, growing acceptance of nutraceuticals and health supplements, and expanding distribution channels provide significant avenues for business growth.
The Company intends to capitalize on these opportunities by identifying suitable products, strengthening its market presence, establishing strategic business relationships and expanding its customer base. As the business matures, the Company expects to enhance its operational capabilities and create long-term value for its stakeholders.
Risks
The healthcare, pharmaceutical and wellness industry is subject to various risks and challenges, including changes in the regulatory framework, stringent quality and compliance requirements, intense market competition and evolving consumer preferences. The Company also faces risks associated with supply chain disruptions, fluctuations in input costs and changing market dynamics. The Company continuously monitors these risks and undertakes appropriate measures to mitigate their impact through effective business planning and regulatory compliance.
Outlook
The Indian healthcare, pharmaceutical and wellness sector is expected to witness sustained growth, supported by increasing demand for preventive healthcare, growing consumer awareness, technological advancements and expanding market opportunities. The Company remains focused on strengthening its business operations, identifying suitable growth opportunities and creating long-term value for its stakeholders while maintaining compliance with the applicable regulatory framework.
Internal Controls and its adequacy
The Company has established internal control systems commensurate with the size, scale and nature of its business. These controls are designed to ensure the orderly and efficient conduct of business operations, safeguarding of assets, accuracy and completeness of accounting records, and compliance with applicable laws and regulations. The internal control systems are reviewed periodically to ensure their adequacy and effectiveness, and necessary improvements are implemented wherever required.
The Company had 2 employees on its rolls as on March 31,2026. There were no significant changes in the key financial ratios during the Financial Year 2025-26, except for the Return on Net Worth, which improved from (17.14%) in the previous financial year to 2.55% during the current financial year, primarily due to the profit earned during the year and the increase in the Companys net worth pursuant to the preferential allotment of equity shares and conversion of warrants into equity shares.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.